Navigation Links
Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
Date:5/6/2008

- Third quarter revenue increased $141 million, or 39 percent, to $504

million on important new product launches - GAAP net income increased 134 percent to $40 million, or $0.42 per share - Adjusted net income increased 100 percent to $44 million, or $0.47 per

share - Refined full year fiscal 2008 adjusted earnings guidance to be in a range of $1.55 to $1.60 per share, with a tax rate in a range of 23% to 27%

ALLEGAN, Mich., May 6 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008.

Perrigo Company

(in thousands, except per share amounts)

Third Quarter Nine Months

2008 2007 2008 2007

Net Sales $503,707 $362,288 $1,321,930 $1,073,132

Net Income $39,967 $17,056 $108,275 $55,026

Adjusted Net Income $44,264 $22,082 $112,572 $60,470

Diluted EPS $0.42 $0.18 $1.14 $0.59

Adjusted Diluted EPS $0.47 $0.24 $1.18 $0.65

Diluted Shares 94,955 93,298 95,115 93,604

These reported results include an acquisition-related write-off of the in- process research and development (IPR&D) of $2.0 million after-tax and a charge for the write-off of the step-up of inventory acquired of $2.1 million after-tax, both related to our January 9, 2008 acquisition of Galpharm Healthcare, Ltd., a leading supplier of over-the-counter store brand pharmaceuti0

Total current liabilities 416,036 379,837 339,487

Non-current liabilities

Long-term debt 697,598 650,762 709,342

Non-current deferred income taxes 112,675 103,775 102,129

Other non-current liabilities 110,512 36,311 34,346

Total non-current liabilities 920,785 790,848 845,817

Shareholders' equity

Preferred stock, without par value,

10,000 shares authorized - - -

Common stock, without par value,

200,000 shares authorized 498,002 519,419 507,025

Accumulated other comprehensive

income 95,398 56,676 34,434

Retained earnings 267,164 178,374 163,798

Total shareholders' equity 860,564 754,469 705,257

$2,197,385 $1,925,154 $1,890,561

Supplemental Disclosures of Balance

Sheet Information

Allowance for doubtful accounts $9,511 $9,421 $9,933

Allowance for inventory $36,962 $36,210 $37,390

Working capital $439,815 $339,223 $373,415

Preferred stock, shares issued - - -

Common stock, shares issued 93,380 93,395 92,510

PERRIGO COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Year-to-Date

2008 2007

Cash Flows (For) From Operating Activities

Net income $108,275 $55,026

Adjustments to derive cash flows

Write-off of in-process

research and development 2,786 8,252

Depreciation and amortization 50,822 41,997

Share-based compensation 6,457 6,530

Deferred income taxes 8,336 12,749

Sub-total 176,676 124,554

Changes in operating assets and

liabilities, net of business and asset

acquisitions and restructuring

Accounts receivable (71,497) (8,616)

Inventories (37,314) (4,224)

Income taxes refundable (4,684) -

Accounts payable 52,513 (19,254)

Payroll and related taxes 6,958 (10,151)

Accrued customer programs (2,445) (9,040)

Accrued liabilities (14,771) 2,968

Accrued income taxes 12,089 3,008

Other 17,969 (5,084)

Sub-total (41,182) (50,393)

Net cash from operating

activities 135,494 74,161

Cash Flows (For) From Investing Activities

Purchases of securities (170,552) (228,341)

Proceeds from sales of securities 201,436 198,530

Additions to property and equipment (26,022) (30,133)

Proceeds from sale of property

and equipment - 2,613

Acquisition of business (87,130) -

Acquisition of assets (12,401) (59,538)

Net cash for investing

activities (94,669) (116,869)

Cash (For) From Financing

Activities

Repayments of short-term debt, net (1,607) (16,293)

Borrowings of long-term debt 140,000 130,000

Repayments of long-term debt (95,801) (30,000)

Tax effect of stock transactions 5,008 (30)

Issuance of common stock 26,097 5,347

Repurchases of common stock (58,979) (20,919)

Cash dividends (13,551) (12,281)

Net cash from financing

activities 1,167 55,824

Net increase in cash and

cash equivalents 41,992 13,116

Cash and cash equivalents,

beginning of period 30,305 19,018

Effect of exchange rate changes on cash (7,895) 2,739

Cash and cash equivalents, end of period $64,402 $34,873

Supplemental Disclosures of Cash

Flow Information

Cash paid/received during the

period for:

Interest paid $29,102 $27,973

Interest received $15,590 $15,119

Income taxes paid $25,715 $8,500

Income taxes refunded $6,560 $8,443

Table I

PERRIGO COMPANY

SEGMENT INFORMATION

(in thousands)

(unaudited)

Third Quarter Fiscal Year

2008 2007 2008 2007

Segment Sales

Consumer Healthcare $373,031 $262,277 $961,495 $780,033

Rx Pharmaceuticals 49,231 34,025 122,846 93,710

API 37,818 30,095 111,240 88,507

Other 43,627 35,891 126,349 110,882

Total $503,707 $362,288 $1,321,930 $1,073,132

Segment Operating Income

(Loss)

Consumer Healthcare $51,693 $21,905 $120,549 $56,770

Rx Pharmaceuticals 11,349 7,615 27,160 17,047

API 6,024 4,238 16,723 14,851

Other 868 1,550 6,922 6,959

Unallocated expenses (7,461) (2,350) (12,925) (10,471)

Write-off of in-process R&D (2,786) (8,252) (2,786) (8,252)

Total $59,687 $24,706 $155,643 $76,904

Table II

PERRIGO COMPANY

RECONCILIATION OF NON-GAAP MEASURES

(in thousands, except per share amounts)

(unaudited)

Third Quarter Fiscal Year

2008 2007 2008 2007

Net sales $503,707 $362,288 $1,321,930 $1,073,132

Reported gross profit $157,946 $99,537 $406,027 $288,859

Inventory step-up 2,878 - 2,878 -

Adjusted gross profit $160,824 $99,537 $408,905 $288,859

Adjusted gross profit % 31.9% 27.5% 30.9% 26.9%

Reported operating income $59,687 $24,706 $155,643 $76,904

Inventory step-up 2,878 - 2,878 -

Restructuring 348 306 348 948

Write-off of in-process R&D 2,786 8,252 2,786 8,252

Adjusted operating income $65,699 $33,264 $161,655 $86,104

Adjusted operating income % 13.0% 9.2% 12.2% 8.0%

Reported net income $39,967 $17,056 $108,275 $55,026

Inventory step-up (1) 2,072 - 2,072 -

Restructuring - Michigan

Plants (2) - 199 - 617

Restructuring - West Coast (3) 219 - 219 -

Write-off of in-process R&D -

Glades acquisition (4) - 4,827 - 4,827

Write-off of in-process R&D -

Galpharm acquisition (1) 2,006 - 2,006 -

Adjusted net income $44,264 $22,082 $112,572 $60,470

Diluted earnings per share

Reported $0.42 $0.18 $1.14 $0.59

Adjusted $0.47 $0.24 $1.18 $0.65

Diluted weighted average

shares outstanding 94,955 93,298 95,115 93,604

(1) Net of taxes at 28%

(2) Net of taxes at 35%

(3) Net of taxes at 37%

(4) Net of taxes at 41.5%

Table II (Continued)

REPORTABLE SEGMENTS

RECONCILIATION OF NON-GAAP MEASURES

(in thousands, except per share amounts)

(unaudited)

Third Quarter Year-To-Date

2008 2007 2008 2007

Consumer Healthcare

Net sales $373,031 $262,277 $961,495 $780,033

Reported gross profit $107,819 $59,560 $266,728 $175,452

Inventory step-up 2,878 - 2,878 -

Adjusted gross profit $110,697 $59,560 $269,606 $175,452

Adjusted gross profit % 29.7% 22.7% 28.0% 22.5%

Reported operating expenses $56,126 $37,655 $146,179 $118,682

Restructuring (348) (306) (348) (948)

Adjusted operating expenses $55,778 $37,349 $145,831 $117,734

Reported operating income $51,693 $21,905 $120,549 $56,770

Inventory step-up 2,878 - 2,878 -

Restructuring 348 306 348 948

Adjusted operating income $54,919 $22,211 $123,775 $57,718

Adjusted operating income % 14.7% 8.5% 12.9% 7.4%

Unallocated

Reported operating loss $(10,247) $(10,602) $(15,711) $(18,723)

Write-off of in-process R&D 2,786 8,252 2,786 8,252

Adjusted operating income

(loss) $(7,461) $(2,350) $(12,925) $(10,471)

Table III

2008 GUIDANCE

RECONCILIATION OF NON-GAAP MEASURES

(unaudited)

Full Year

Fiscal 2008 Guidance

Reported earnings per share range $1.48 - $1.53

Write-off of in-process R&D $0.021

Inventory step-up $0.044

Restructuring $0.004

Adjusted earnings per share range $1.55 - $1.60

cals in the United Kingdom. (Refer to Table II at the end of this press release for additional adjustments in the current year and prior year periods and additional non-GAAP disclosure information.)

Third Quarter results

Net sales for the third quarter of fiscal 2008 were a record $503.7 million, an increase of $141.4 million, or 39 percent, compared with $362.3 million last year. Reported net income was $40.0 million, or $0.42 per share, compared with net income of $17.1 million, or $0.18 per share a year ago. In the third quarter of fiscal 2008 and fiscal 2007, the Company recorded several net of tax charges, summarized as follows:

2008 2007

-- Write-off of IPR&D $2.0 $4.8

-- Inventory step-up 2.1 -

-- Restructuring 0.2 0.2

$4.3 $5.0

Excluding the impact of the charges noted above, adjusted net income for the third quarter of fiscal 2008 was $44.3 million, or $0.47 per share. For the third quarter of fiscal year 2007, adjusted net income was $22.1 million, or $0.24 per share.

(Refer to Table II at the end of this press release for additional non- GAAP disclosure information.)

Perrigo's Chairman and CEO Joseph C. Papa commented, "For the second quarter in a row, we delivered record sales and earnings with successful launches of two of the largest products in our 120 year history, Omeprazole and Cetirizine. We also began shipping products from our Galpharm acquisition in the United Kingdom and launched Clobetasol Foam in Rx. The results this quarter clearly show the benefits of our long term commitment to our new product pipeline."

Nine Months Results

Net sales for the nine months ended March 29, 2008 were $1,321.9 million, compared with $1,073.1 million last year, an increase of $249 million, or 23 percent. Reported net income for the nine months was $108.3 million, or $1.14 per share, compared with $55.0 million, or $0.59 per share last year. In the first nine months of fiscal 2008 and fiscal 2007, the Company recorded several net of tax charges, summarized as follows:

2008 2007

-- Write-off of IRP&D $2.0 $4.8

-- Inventory step-up 2.1 -

-- Restructuring 0.2 0.6

$4.3 $5.4

Excluding the impact of the charges noted above, adjusted net income for the nine months of fiscal 2008 was $112.6 million, or $1.18 per share. For the nine months of fiscal 2007, adjusted net income was $60.5 million, or $0.65 per share.

(Refer to Table II at the end of this press release for additional non- GAAP disclosure information.)

Consumer Healthcare

Consumer Healthcare segment net sales for the quarter were a record $373 million, up $111 million, or 42 percent, compared with $262 million last year. The sales increase included $97 million in new product revenue, led by Omeprazole and Cetirizine, strong sales in the cough/cold, analgesic and smoking cessation product categories. Reported operating income was $51.7 million, compared with $21.9 million last year. Adjusted operating income was $54.9 million, compared with adjusted operating income of $22.2 million a year ago.

On December 28, 2007, Perrigo announced it received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for OTC Cetirizine Hydrochloride Tablets, 5 and 10 mg. The product is being marketed under store brand labels and is comparable to McNeil Consumer Healthcare's Zyrtec(R) Tablets. Store brand shipments began in January.

On January 9, 2008, the Company announced it acquired Galpharm Healthcare, Ltd., a leading United Kingdom-based supplier of over-the-counter store brand products, for approximately $87 million. The acquisition is expected to add more than $55 million in net sales annually and be accretive to earnings in the first 12 months.

On March 4, 2008, Perrigo announced that it began shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at the same dose as Prilosec OTC(R) and is indicated for the treatment of frequent heartburn.

For the first nine months of fiscal 2008, Consumer Healthcare net sales were $961.5 million, up $181.5 million, or 23 percent, compared with $780.0 million last year. The sales gain was driven by new product sales of $117 million, largely Omeprazole, Cetirizine and Smoking Cessation products. Reported operating income was $120.5 million, compared with $56.8 million a year ago. Adjusted operating income was $123.8 million, compared with adjusted operating income of $57.7 million last year.

Rx Pharmaceuticals

The Rx Pharmaceutical segment reported third quarter net sales of $49.2 million, including $3.1 million of service and royalty revenue and an $8.5 million payment for termination of a license agreement. This represents an increase of $15.2 million, or 45 percent, compared with $34.0 million last year, of which $5.8 million was service and royalty revenue. Operating income was $11.3 million, up from $7.6 million a year ago, as a result of increased volume and improved margins.

For the first nine months of fiscal 2008, net sales were $122.8 million, including $11.9 million of service and royalty revenue and an $8.5 million payment for termination of a license agreement, resulting in an increase of $29.1 million, or 31 percent, compared with $93.7 million last year, of which $15.8 million was service and royalty revenue. Operating income was $27.2 million, up $10.2 million, or 60 percent, from $17.0 million in the year-ago period.

API

API segment third quarter net sales were $37.8 million, compared with $30.1 million last year, an increase of 26 percent. Operating income was $6.0 million, compared with $4.2 million last year. API performance in the quarter benefited from a one-time $4.9 million accrual reversal related to a long standing customer contract negotiation. For the first nine months of fiscal 2008, net sales were $111.2 million, up $22.7 million, or 26 percent from $88.5 million last year. Operating income was $16.7 million, compared with $14.9 million a year ago.

Other

The Other category, consisting of Israel Consumer Products and Israel Pharmaceutical and Diagnostic Products segments, reported third quarter net sales of $43.6 million, compared with $35.9 million a year ago, an increase of 22 percent. Operating income was $0.9 million, compared with $1.6 million last year. For the first nine months of fiscal 2008, net sales were $126.3 million, up $15.4 million, or 14 percent, compared with $110.9 million last year. Operating income was $6.9 million, compared with $7.0 million last year.

Unallocated Expenses

In the third quarter of fiscal 2008, unallocated expenses were $10.2 million, compared with $10.6 million a year ago. Both periods included an acquisition-related write-off of IPR&D. These pre-tax expenses were $2.8 million and $8.3 million, respectively. For the nine months in fiscal 2008, unallocated expenses were $15.7 million, compared with $18.7 million last year. Both periods included acquisition-related write-offs of IPR&D, which were $2.8 million and $8.3 million, respectively.

Outlook

The Company has refined its expected range of adjusted EPS for the full fiscal year to $1.55 to $1.60 per share, excluding acquisition and restructuring related charges. It has increased its full-year tax rate expectations to a range of 23 to 27 percent. The Company still expects to generate cash from operations in the range of $180 million to $200 million for the full fiscal year.

(Refer to Table III at the end of this press release for additional non- GAAP earnings guidance disclosure information.)

Perrigo's Chairman and CEO Joseph C. Papa concluded, "In this dynamic environment, our focus continues to be executing our plan, maintaining quality, improving our customer service and lowering working capital. While we are very pleased with our performance to date, there is always work to be done to continue launching quality, affordable new healthcare products into the marketplace."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PERRIGO COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(unaudited)

Third Quarter Year-to-Date

2008 2007 2008 2007

Net sales $503,707 $362,288 $1,321,930 $1,073,132

Cost of sales 345,761 262,751 915,903 784,273

Gross profit 157,946 99,537 406,027 288,859

Operating expenses

Distribution 7,987 7,020 22,805 21,559

Research and development 19,160 16,390 51,623 44,339

Selling and

administration 67,978 42,863 172,822 136,857

Subtotal 95,125 66,273 247,250 202,755

Write-off of in-process

research and development 2,786 8,252 2,786 8,252

Restructuring 348 306 348 948

Total 98,259 74,831 250,384 211,955

Operating income 59,687 24,706 155,643 76,904

Interest, net 3,688 3,650 12,017 11,536

Other (income) expense, net 448 (699) (637) (2,919)

Income before income taxes 55,551 21,755 144,263 68,287

Income tax expense 15,584 4,699 35,988 13,261

Net income $39,967 $17,056 $108,275 $55,026

Earnings per share

Basic $0.43 $0.19 $1.16 $0.60

Diluted $0.42 $0.18 $1.14 $0.59

Weighted average

shares outstanding

Basic 92,854 91,643 93,127 92,161

Diluted 94,955 93,298 95,115 93,604

Dividends declared per share $0.050 $0.045 $0.145 $0.133

PERRIGO COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

March 29, June 30, March 31,

2008 2007 2007

Assets (unaudited) (unaudited)

Current assets

Cash and cash equivalents $64,402 $30,305 $34,873

Investment securities 725 49,110 58,220

Accounts receivable 372,526 282,045 246,582

Inventories 356,906 295,114 310,272

Current deferred income taxes 37,716 41,400 39,122

Income taxes refundable 4,684 - -

Assets held for sale 2,746 2,746 -

Prepaid expenses and other current

assets 16,146 18,340 23,833

Total current assets 855,851 719,060 712,902

Property and equipment 708,297 664,096 641,343

Less accumulated depreciation 372,618 333,024 320,672

335,679 331,072 320,671

Restricted cash 400,000 422,000 422,000

Goodwill 264,913 196,218 189,450

Other intangible assets 231,033 159,977 159,427

Non-current deferred income taxes 51,033 54,908 42,624

Other non-current assets 58,876 41,919 43,487

$2,197,385 $1,925,154 $1,890,561

Liabilities and Shareholders' Equity

Current liabilities

Accounts payable $229,744 $164,318 $158,499

Notes payable 10,169 11,776 3,763

Payroll and related taxes 54,849 46,226 43,590

Accrued customer programs 45,773 48,218 40,494

Accrued liabilities 39,039 47,333 48,135

Accrued income taxes - 29,460 16,210

Current deferred income taxes 18,864 17,125 13,886

Current portion of long-term debt 17,598 15,381 14,91
'/>"/>

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
3. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
4. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
5. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
6. Perrigo Company Announces Launch of Clobetasol Propionate Foam
7. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
8. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
9. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
10. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan ... The purpose of these scholarships is to encourage applicants to pursue a degree in ... within these two parishes. , “We have available jobs in St. Landry and ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... /PRNewswire/ - Demers Ambulances announces its first delivery in the state ... County Emergency Medical Services (EMS) consisting of four ... van. Quality Emergency Vehicles in Lecanto, FL ... This is the latest in Demers, ongoing expansion of sales.  ... Demers. --> Benoit LaFortune , Executive Vice President ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology: